Payment overview · 2025
General Payments
$358.89
15 reported records · 11 companies
Healthcare provider profile · identity verified
Sanjeev Puri, D.O
Allopathic & Osteopathic Physicians|Family Medicine · WHITTIER, CA · NPI 1730420399
Verified facts
What the public records show
CMS Open Payments records show Sanjeev Puri, D.O received $358.89 in general payments during 2025 across 15 reported records.
Amgen Inc. accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $63.33 | 17.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.19 | 11.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.91 | 10.8% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $38.90 | 10.8% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $32.86 | 9.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $31.10 | 8.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.78 | 8.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.29 | 8.2% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $25.93 | 7.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.49 | 4.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.11 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $358.89 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $63.33 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $63.33 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $40.19 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.91 | 2 | 2025 |
Source payment records
|
|||||
| VSP SYSTEM, VSP CRANIAL Normalized: vsp system vsp cranial |
Device | Stryker Corporation | $38.90 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $32.86 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $31.10 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $25.93 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
133 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 534 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 333 | 59 |
| Losartan Potassium | Losartan Potassium | 301 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 288 | 77 |
| Metformin Hcl | Metformin Hcl | 282 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 276 | 62 |
| Gabapentin | Gabapentin | 263 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 211 | 28 |
| Furosemide | Furosemide | 198 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 40 |
| Eliquis | Apixaban | 165 | 26 |
| Carvedilol | Carvedilol | 163 | 32 |
| Trazodone Hcl | Trazodone Hcl | 136 | 35 |
| Jardiance | Empagliflozin | 133 | 24 |
| Lisinopril | Lisinopril | 124 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 101 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 19 |
| Omeprazole | Omeprazole | 97 | 30 |
| Famotidine | Famotidine | 89 | 23 |
| Sertraline Hcl | Sertraline Hcl | 89 | 19 |
| Mirtazapine | Mirtazapine | 87 | 21 |
| Donepezil Hcl | Donepezil Hcl | 84 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 12 |
| Lorazepam | Lorazepam | 78 | 16 |
| Simvastatin | Simvastatin | 78 | 15 |
| Azithromycin | Azithromycin | 73 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 68 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 30 |
| Potassium Chloride | Potassium Chloride | 65 | 17 |
| Enulose | Lactulose | 62 | 16 |
| Alendronate Sodium | Alendronate Sodium | 58 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 19 |
| Divalproex Sodium | Divalproex Sodium | 55 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 55 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 33 |
| Celecoxib | Celecoxib | 51 | 14 |
| Tramadol Hcl | Tramadol Hcl | 51 | 27 |
| Levetiracetam | Levetiracetam | 50 | suppressed |
| Allopurinol | Allopurinol | 46 | 11 |
| Montelukast Sodium | Montelukast Sodium | 46 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 14 |
| Pregabalin | Pregabalin | 45 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Prednisone | Prednisone | 41 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 41 | 16 |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 29 |
| Finasteride | Finasteride | 40 | 13 |
| Risperidone | Risperidone | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 29 |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 15 |
| Levofloxacin | Levofloxacin | 34 | 29 |
| Meclizine Hcl | Meclizine Hcl | 34 | 15 |
| Baclofen | Baclofen | 33 | 12 |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 12 |
| Lactulose | Lactulose | 32 | 14 |
| Pentoxifylline | Pentoxifylline | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 24 |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Latanoprost | Latanoprost | 30 | 12 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | 11 |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Budesonide | Budesonide | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 19 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Nexletol | Bempedoic Acid | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 16 |
| Olanzapine | Olanzapine | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Calcium Acetate | Calcium Acetate | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | 12 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 18 | suppressed |
| Humulin R | Insulin Regular, Human | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 14 |
| Spironolactone | Spironolactone | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | 11 |
| Digoxin | Digoxin | 16 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 16 | suppressed |
| Tivicay | Dolutegravir Sodium | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 12 |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 14 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Olanzapine Odt | Olanzapine | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Valsartan | Valsartan | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Ertapenem | Ertapenem Sodium | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Lamivudine | Lamivudine | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $358.89 · 15 records | Amgen Inc. | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), GVOKE HYPOPEN, Kerendia, Korlym, MOUNJARO, OTEZLA, QUTENZA, REPATHA, TRELEGY ELLIPTA, VSP SYSTEM, VSP CRANIAL, Veozah, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error